Our preferred technique to produce ASDs is spray drying. After spray drying, we formulate the ASD powder into a final dosage form. In the discovery or preclinical stage, ASD powders are typically dispersed in a liquid vehicle prior to administration to laboratory animals. In this scenario, it is key to develop an administration vehicle that prevents premature API crystallisation. You can learn more
here about some of the tactics we recommend when developing a gavage formulation.
For early clinical use, we generally recommend powder-filled capsules. Key here is to optimise for rapid disintegration as slow disintegration on contact with water may dramatically reduce ASD performance due to local API supersaturation and subsequent crystallisation.